Oral News and Research

RSS

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.

6 Sep 2011

Researchers discover how yeast cells identify, attach to human tissue and cause infection

Researchers are a step closer towards creating a new class of medicines and vaccines to combat drug-resistant and deadly strains of fungal infections, following a new study published today in Proceedings of the National Academy of Sciences.

6 Sep 2011

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces oral communication of the Phase II clinical trial results of its orphan product Livatag at the annual congress of ILCA, the only international organization devoted exclusively to liver cancer research with participation of worldwide best specialists.

6 Sep 2011

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Gilead Sciences, Inc. today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.

5 Sep 2011

Berlin to market wide range of Acino Pharma's current and future products in Thailand

Berlin Pharmaceutical Industry Co., Ltd. and Acino Pharma AG signed a long term partnership agreement under which Berlin will market a wide range of the Swiss company's current and future products in Thailand.

5 Sep 2011

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation.

3 Sep 2011

Simulation training helps students to score more on final examinations

Medical students who practiced on a patient simulator before assisting in real-life vaginal deliveries scored significantly higher on their final examinations than did students receiving a lecture only at the start of an obstetric clerkship.

3 Sep 2011

Key international experts to attend major European bone congress in Bourse, France

Key international experts in the bone field are to be featured speakers and session leaders at the upcoming European Congress on Osteoporosis & Osteoarthritis (IOF-ECCEO12). As the major European bone event of the year, IOF-ECCEO12 will present the latest research and clinical advances in the bone field.

3 Sep 2011

Sand fly's salivary components play a critical role in process for Leishmania

For millions of people who live under the constant threat of Leishmania infection, a new discovery by Brazilian scientists may lead to new breakthroughs, preventing these parasites from taking hold in the body or reducing the severity of infections once they occur.

2 Sep 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011

HPV vaccination drives to prevent cervical cancers

Mexico plans to administer the vaccine against human papillomavirus (HPV), which can cause cervical cancer, to all girls beginning next year, the country's health ministry said Tuesday.

31 Aug 2011

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Aeterna Zentaris Inc. today announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency.

31 Aug 2011

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

Aeterna Zentaris Inc. today announced that a poster on its novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado.

30 Aug 2011

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

ZIOPHARM Oncology, Inc. today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma.

30 Aug 2011

AstraZeneca: BRILIQUE receives Class I recommendation from ESC

AstraZeneca today announced BRILIQUE, a new oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised "Guidelines for Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation."

30 Aug 2011

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.

30 Aug 2011

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Researchers find that an experimental anticlotting pill Eliquis is more effective than standard drug, warfarin, at preventing strokes in people with a heart condition that puts them at high risk of blood clots and stroke. The new drug also known as apixaban, cut the risk of stroke by 21% compared with warfarin in people with atrial fibrillation (AF). It lowered the risk of dying by 11%.

30 Aug 2011

Affinium closes $15 million financing round

Affinium Pharmaceuticals announced today the closing of its $15 million financing. Investors participating in the financing include all three of Affinium's Series A investors, SV Life Sciences, Genesis Capital Partners and Forward Ventures, along with the addition of the Ontario Emerging Technologies Fund (OETF) to the syndicate.

29 Aug 2011

Post myocardial infarction snus quitters have 44% lower risk of mortality

In this prospective cohort study, presented today at the ESC Congress 2011, discontinuation of smokeless tobacco after a myocardial infarction (MI) is associated with a lower risk of subsequent mortality. Investigators found that post MI snus quitters had a 44 % lower risk of total mortality.

29 Aug 2011

Study shows feasibility of combined postprandial glucose and triglyceride tolerance testing

The Homburg Cream and Sugar (HCS) study was designed to determine whether the measurement of postprandial triglyceride in addition to the assessment of glucose tolerance and traditional risk factors might improve the prediction of cardiovascular events.

29 Aug 2011

Oral News and Research

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

Researchers discover how yeast cells identify, attach to human tissue and cause infection

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Berlin to market wide range of Acino Pharma's current and future products in Thailand

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Simulation training helps students to score more on final examinations

Key international experts to attend major European bone congress in Bourse, France

Sand fly's salivary components play a critical role in process for Leishmania

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

HPV vaccination drives to prevent cervical cancers

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

AstraZeneca: BRILIQUE receives Class I recommendation from ESC

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Affinium closes $15 million financing round

Post myocardial infarction snus quitters have 44% lower risk of mortality

Study shows feasibility of combined postprandial glucose and triglyceride tolerance testing

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News